A trial looking at chemotherapy for young people with Hodgkin lymphoma (The 18 to 30 study)

Cancer type:

Blood cancers
Hodgkin lymphoma




Phase 2

This was a trial to see if chemotherapy used to treat children who have Hodgkin lymphoma could also help young adults. This trial was supported by Cancer Research UK.

Doctors usually treat Hodgkin lymphoma with chemotherapy and radiotherapy. The most commonly used chemotherapy for Hodgkin lymphoma is called ABVD.

Children diagnosed with Hodgkin lymphoma in some European countries are now treated with another chemotherapy regimen. We know from research that this gives them a better chance of cure than adults who have standard chemotherapy.

In this trial, the researchers wanted to find out if a chemotherapy regimen similar to the one used for children could help young adults with Hodgkin lymphoma more than the standard adult treatment.

The aims of the trial were to

  • Find out if chemotherapy adapted from the children’s regimen helped young adults with Hodgkin lymphoma
  • Learn more about the side effects

Summary of results

The trial team found that the adapted chemotherapy regimen did help young adults with Hodgkin lymphoma.

This was a phase 2 trial. It recruited 47 people between the ages of 18 and 30. Everyone had the adapted chemotherapy regimen followed by radiotherapy if needed. The adapted chemotherapy regimen included

Of the 47 young adults recruited, 45 completed their chemotherapy. One young adult withdrew their consent before starting treatment and another was withdrawn from the trial because they had a severe reaction to one of the drugs.  

After an average follow up of 1½ years, the lymphoma had come back in only 4 of the young adults.  

The side effects of treatment were

The trial team concluded that the results showed that the adapted chemotherapy regimen could help young adults with Hodgkin lymphoma. They think that future trials could compare this regimen (or a similar one) with ABVD as treatment for young adults with Hodgkin lymphoma.   

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) but may not have been published in a medical journal.  The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Kirit Ardeshna

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)

Other information

This is Cancer Research UK trial number CRUK/08/012.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 2112

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page